Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia

Journal of Medical Microbiology

Volumn 59, Issue 12, 2010, Pages 1530-1532

  Ahmad, Norazah ^a   Nawi, Salbiah ^b   Rajasekaran, Ganeswrie ^c   Maning, Nurahan ^d   Aziz, Mohamad Nazri ^e   Husin, Azura ^f   Rahman, Nor Iza Abdul ^g  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b Selayang Hospital   (Malaysia)

^c HOSPITAL SULTANAH AMINAH   (Malaysia)

^d Hospital Raja Perempuan Zainab II   (Malaysia)

^e HOSPITAL KUALA LUMPUR   (Malaysia)

^f Queen Elizabeth Hospital   (Malaysia)

^g Penang Adventist Hospital   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; EPSILOMETER TEST; HUMAN; LETTER; MALAYSIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INDONESIA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 78649408850     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.022079-0     Document Type: Letter

References (19)

1. CLSI (2006). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard, 7th edn, M7-A7, vol. 26 no. 2. Wayne, PA: Clinical and Laboratory Standards Institute.
2. CLSI (2009). Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement. M100-S19, vol. 29 no. 3. Wayne, PA: Clinical and Laboratory Standards Institute.
3. Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A. & Wong-Beringer, A. (2006). High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166, 2138-2144. (Pubitemid 44631403)
4. Ho, P. L., Lo, P. Y., Chow, K. H., Lau, E. H., Lai, E. L., Cheng, V. C. & Kao, R. Y. (2010). Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 60, 140-145.
5. Hsu, D. I., Hidayat, L. K., Quist, R., Hindler, J., Karslsson, A., Yusof, A. & Wong-Beringer, A. (2008). Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32, 378-385.
6. Liu, C. & Chambers, H. F. (2003). Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47, 3040-3045. (Pubitemid 37229554)
7. Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M. & Stellrecht, K. (2008). Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteraemia treated with vancomycin. Antimicrob Agents Chemother 52, 3315-3320.
8. Ministry of Health (2008). National Surveillance of Antibiotic Resistance Report. Malaysia: Ministry of Health. http://www.imr.gov.my/report/nsar.htm
9. Moise, P. A. & Schentag, J. J. (2000). Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16, S31-S34. (Pubitemid 32007934)
10. Moise, P. A., Smyth, D. A., El-Fawal, N., Robinson, D. A., Holden, P. N., Forrest, A. & Sakoulas, G. (2008). Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 61, 85-90.
11. Norazah, A., Salbiah, N., Nurizzat, M. & Santhana, R. (2009). Vancomycin treatment failure in a vancomycin susceptible methicillin-resistant Staphylococcus aureus (MRSA) infected patient. Med J Malaysia 64, 166-167.
12. Prakash, V., Lewis, J. S. & Jorgensen, J. H. (2008). Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52, 4528.
13. Robert, J., Bismuth, R. & Jarlier, V. (2006). Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 57, 506-510. (Pubitemid 43240204)
14. Sader, H. S., Rhomberg, P. R. & Jones, R. N. (2009). Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53, 3162-3165.
15. Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forest, A., Moellering, R. C. & Eliopoulos, G. M. (2004). Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 42, 2398-2402. (Pubitemid 38747480)
16. Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J. & Mensa, J. (2008). Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 46, 193-200. (Pubitemid 351269157)
17. Steinkraus, G., White, R. & Friedrich, L. (2007). Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillinresistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60, 788-794. (Pubitemid 47434257)
18. Walsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P. & Diekema, D. (2001). Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39, 2439-2444. (Pubitemid 32606216)
19. Wang, G., Hindler, J. F., Ward, K. W. & Bruckner, D. A. (2006). Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44, 3883-3886. (Pubitemid 44737223)